By Paulo Fernandes & Lucas Ariel Fernandes
The biotechnology industry currently faces significant challenges, especially for early-stage companies trying to navigate the complex “Valley of Death.” This term refers to the critical phase in which biotechnology startups, brimming with innovative potential, struggle to secure the funding and support needed to progress from discovery to clinical development and, eventually, to market entry.
Historically, this phase has been perilous due to high drug development costs, long lead times, and the uncertainty of scientific success. These factors have made investors cautious, often leading to a lack of financial support just when it is most needed. As a result, many promising biotechnologies fail to advance, not because they lack potential, but because they cannot bridge the financial gap between early research and commercial viability.
Access to financing for these companies
Recent market conditions have exacerbated this challenge. While innovation in the biotech sector is booming—with advances in areas such as AI-driven drug discovery, personalized medicine, and complex therapies—funding has become increasingly difficult. Public markets are tight, and traditional venture capitalists are more cautious, prioritizing late-stage companies with proven clinical assets and potential $1 billion in the first year of sale (a new blockbuster with Ozempic) over early-stage startups that are still in the development phase.
This environment has created a sharp divide in the biotech landscape. On one side are well-funded, clinical-stage companies advancing their pipelines toward regulatory approval. On the other are early-stage startups that, despite their innovative approaches and potential for breakthrough therapies, struggle to attract the investment needed to propel their projects forward.
Despite this scenario of scarcity, there is still room for large investment rounds, as is the case of Mirador Therapeutics and BioAge Labs, which raised US$400 and 170 million dollars respectively, in March of this year.¹ Companies such as CG Oncologia and Kyverna Therapeutics raised around US$300 million dollars with the IPO, although a shadow of times gone by, shows that for companies positioned in strategic areas and in advanced stages of development, there is opportunity, as is the case of HI-BIO, a company that develops immunotherapy for advanced autoimmune diseases, in clinical phase with studies in phases II and III and which was acquired by Biogen for US$1.8 billion dollars. What is the "secret", if there is one, to guarantee large fundraising and acquisitions?
What kind of solutions can be found
For these startups to overcome these challenges, it is crucial to have service providers that are the right size, that offer flexible and innovative compensation models, and that align part of their remuneration with the success of the project. This is especially important in countries with less tradition in radical innovation, where proper management of the process, with the support of governments, associations, sectors and other stakeholders, is essential to ensure progress. Although this is an interesting reading, it is still rare for there to be actors within the ecosystem who are interested in sharing risks, even partially. This often leads to fundamental steps in the development process, often those associated with regulatory compliance, being somehow neglected, which in the future delays or makes progress in the development of some of these innovations unfeasible.
In Brazil, for example, the government has been promoting programs that support innovation with the aim of feeding the Unified Health System (SUS). Initiatives such as technology orders are gaining significant importance and in some cases are essential in a universal health system, as they ensure that innovation is aligned with the country's public health needs. In addition, these orders encourage the development of specific technological solutions that can be absorbed by the health system, promoting continuous and sustainable improvements. This is a major investment being made by the Brazilian government at this time.
However, signs of recovery are beginning to emerge. The number of biotech IPOs is increasing, and corporate venture capital is filling some of the gaps left by traditional VCs. These investors are particularly interested in companies that can demonstrate a clear path to clinical success, especially in high-demand therapeutic areas such as oncology, neurology, and obesity. The role of strategic partnerships and collaborations is also becoming more prominent as companies seek cost-effective solutions to address the financial challenges of drug development.
What's coming next
Despite the challenges, there is optimism in the industry. Savvy investors recognize that the current slowdown presents an opportunity to invest in undervalued assets with significant upside potential. Furthermore, the growing interest in AI and other digital technologies offers a new avenue for companies to enhance their R&D capabilities, potentially shortening development timelines and reducing costs.
To successfully navigate the Valley of Death, biotech companies must not only focus on scientific innovation, but also adopt smarter and more flexible business strategies. This includes leveraging non-traditional funding sources, exploring innovative compensation models that align the interests of investors and companies, and forming strategic alliances that provide both financial and operational support.
Conclusion
In summary, while the biotechnology sector is undoubtedly facing a challenging period, there is a sense of cautious optimism. With the right combination of innovation, strategic planning, government support and financial backing, companies can overcome current obstacles and emerge stronger, contributing to the next wave of medical advancements.
About the Author Contributor Lucas Ariel Fernandes
Graduated in Nursing from the State University of Piauí, PhD in Pharmacology from the Institute of Biomedical Sciences at USP- São Paulo, working in the line of pharmacogenomics, metabolic diseases, non-alcoholic steatohepatitis, microRNAs, gene therapy.
He participated in the Biostartup Lab entrepreneurship program with the spin-off ABL Therapeutics. He participated in the Emerge Labs life sciences entrepreneurship program. Founder of the company Mirscience Therapeutics, to which he currently dedicates himself full-time.
About Mirscience
MirScience Therapeutics is a biotechnology startup focused on developing therapies using non-coding RNAs to address diseases associated with longevity. Its main research areas include muscle atrophy conditions such as sarcopenia and cancer-induced cachexia, as well as metabolic diseases such as non-alcoholic steatohepatitis (NASH) and liver fibrosis.
The company uses its proprietary GOAT platform to identify specific therapeutic targets and develop oligonucleotides that target undesirable targets. Its most advanced molecule, MT-29, has shown promising results in preclinical trials for regenerating muscle mass and reversing muscle atrophy, offering a solution for diseases that cause muscle weakness and fragility.
MirScience's mission is to improve patients' quality of life by providing safe, targeted and affordable therapies that address unmet medical needs related to aging and chronic disease.
References
留言